N. Khan

发表

Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma

R. Advani, A. Zelenetz, J. Friedberg, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?

A. Moskowitz, N. Khan, 2017, Current Hematologic Malignancy Reports.

Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment

J. Feliciano, M. Rebeira, M. Matasar, 2020, Leukemia & lymphoma.

Peripheral T-cell lymphoma - are we making progress?

S. Horwitz, A. Dogan, A. Moskowitz, 2018, Best practice & research. Clinical haematology.

Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia

R. Larson, W. Stock, R. Knoebel, 2017, Leukemia & lymphoma.

The experience of financial toxicity among advanced melanoma patients treated with immunotherapy

S. Baxi, D. Korenstein, R. Sidlow, 2020, Journal of psychosocial oncology.

Plaque brachytherapy for uveal melanoma: a vision prognostication model.

R. Macklis, J. Bena, Arun D. Singh, 2012, International journal of radiation oncology, biology, physics.

Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents

R. Macklis, M. K. Khan, Alex Almasan, 2011, OncoTargets and therapy.

The evolving role of radiation therapy in the management of malignant melanoma.

R. Macklis, Arun D. Singh, Alex Almasan, 2011, International journal of radiation oncology, biology, physics.

Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry

M. Federico, C. Gisselbrecht, S. Horwitz, 2019, American journal of hematology.

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Christopher A. Miller, R. Wilson, R. Fulton, 2016, The New England journal of medicine.

Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study.

Y. Taur, A. Bush, E. Pamer, 2020, Blood.

Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation.

Daigo Hashimoto, Robert R Jenq, Amy Bush, 2020, The New England journal of medicine.

How we treat mycosis fungoides and Sézary syndrome.

S. Horwitz, S. Noor, N. Khan, 2021, Clinical advances in hematology & oncology : H&O.

Psychological morbidities in adolescent and young adult blood cancer patients during curative‐intent therapy and early survivorship

W. Stock, C. Daugherty, K. Wroblewski, 2016, Cancer.

S. Baxi, D. Korenstein, R. Gennarelli, 2018, British Medical Journal.

Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors

S. Baxi, M. Postow, J. Mao, 2020, Journal for ImmunoTherapy of Cancer.

Pilot Trial of Homebound Hematopoietic Cell Transplantation.

M. Perales, S. Devlin, A. Applebaum, 2022, Transplantation and cellular therapy.

Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)

V. Seshan, A. Zelenetz, O. Abdel-Wahab, 2021, Blood.

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

V. Seshan, G. Salles, A. Zelenetz, 2022, Blood Cancer Journal.

Immunotherapy in mycosis fungoides: opening night or dress rehearsal?

S. Horwitz, N. Khan, 2019, Leukemia & lymphoma.

Dermatologic adverse events of brentuximab vedotin: Characteristics, management, and their relationship with dose regimen.

M. Pulitzer, N. Kurtansky, S. Noor, 2021 .

Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Cutaneous T Cell Lymphoma.

J. Nelson, Jennifer A. Salant, A. Desai, 2021, Journal of palliative medicine.

Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant

E. Pamer, M. Perales, R. Jenq, 2018, Blood.

PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DACARBAZINE (N‐AVD) AS FRONTLINE THERAPY IN OLDER ADULTS WITH HODGKIN LYMPHOMA

K. Savage, H. Schoder, A. Dogan, 2023, Hematological Oncology.

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

R. Advani, A. Zelenetz, J. Friedberg, 2022, Blood.

Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents

R. Macklis, Roger R Macklis, Mohammad K. Khan, 2011 .

Test yourself: soft tissue mass in elbow

M. Hameed, A. Lombardi, Sinchun Hwang, 2023, Skeletal Radiology.

Retrospective characterization of nodal marginal zone lymphoma

A. Zelenetz, S. Horwitz, A. Intlekofer, 2023, Blood advances.